[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354587-105":59,"doc-detail-354587-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","induced-proximity-based-therapeutics-for-advanced-prostate-cancer","Induced proximity-based therapeutics for advanced prostate cancer","","Metastatic castration-resistant prostate cancers (mCRPC) persistently depend on androgen receptor (AR) signaling even after androgen-deprivation and AR-targeted treatments. Induced proximity-based therapeutics use event-driven pharmacology to engage AR through transient catalytic activity, potentially bypassing resistance mechanisms. Recent advances highlight AR-inducing strategies, including PROTACs and RIPTACs, aimed at suppressing or exploiting AR expression for CRPC intervention and improved durability beyond conventional inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/induced-proximity-based-therapeutics-for-advanced-prostate-cancer/354587/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/induced-proximity-based-therapeutics-for-advanced-prostate-cancer/354587.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do metastatic castration-resistant prostate cancers remain dependent on androgen receptor signaling?","Question",{"text":112,"@type":113},"mCRPC continues to rely on AR signaling despite androgen-deprivation and AR-targeted therapies, often through mechanisms that compensate for AR suppression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do induced proximity-based therapeutics differ from occupancy-based inhibitors?",{"text":117,"@type":113},"Induced proximity-based drugs act via event-driven pharmacology, where transient catalytic activity enables target-effector interaction, rather than directly inhibiting the target through occupancy.",{"name":119,"@type":110,"acceptedAnswer":120},"What are PROTACs and what is their main mechanism?",{"text":121,"@type":113},"PROTACs are heterobifunctional molecules that bring an E3 ligase and a protein of interest into proximity, promoting polyubiquitination and degradation through the ubiquitin-proteasome system.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354587,1790172645,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","npj | drug discovery Perspective  \n\n| \u003Cbr>[https://doi.org/10.1038/s44386-026-00062-5](https://doi.org/10.1038/s44386-026-00062-5) |  |\n| --- | --- |\n| Induced proximity-based therapeutics for advanced prostate cancer\u003Cbr> Check for updates |  |\n| John Ching1, Cindy H. Chau2 & William D. Figg1,2  |  |\n| Metastatic castration-resistant prostate cancers (mCRPC) remain dependent on androgen receptor (AR) signaling despite resistance to androgen-deprivation and AR-targeted therapies. Induced proximity-based therapeutics employ event-driven pharmacology to target AR, potentially overcoming resistance mechanisms. Herein, we highlight recent advances in induced proximity strategies targeting AR in mCRPC. |  |\n| Following Charles B. Huggins’s landmark publication on the effects of testosterone suppression for the treatment of advanced prostate cancer1, androgen deprivation therapy (ADT) has become a mainstay in prostate cancer management. However, tumors that become unresponsive to such treatment will inevitably progress as castration-resistant prostate cancer (CRPC). While the addition of androgen receptor pathway inhibitors (ARPIs) and taxanes to standard ADT has led to signiﬁcantly improved outcomes, emerging resistance to these drugs necessitates the discovery of new alternative pathways of treatment. Although there are subsets of metastatic CRPC(mCRPC)lacking in androgen receptor(AR)dependency, many cases of mCRPC still rely on AR signaling but have developed mechanisms that compensate for AR suppression, such asARampliﬁcation, mutations that affect drug binding, and changes in the biosynthesis pathway of androgens2. Thus, AR targeting in mCRPC provides both a unique challenge and opportunity: while the targeting of AR signaling and expression remains a highly selective factor formCRPC, the development of a variety of resistance pathways prevents successful intervention by standard-of-care treatment. As such, additional pathways capable of either suppressing the androgen receptor axis or exploiting its expression in mCRPC despite these resistances are vital to overcoming castration resistance.\u003Cbr>Induced proximity-based therapeutics area growingﬁeldofdrugs that aim to bypass traditional chemotherapeutic resistance. These drugs rely on“event-driven pharmacology”, in which their pharmacological effect is mediated through transient catalytic activity. This results in the interaction of a target and effector molecule, as opposed to “occupancy-based” inhibitors that inhibit their target molecule directly. While diverse in their speciﬁc mechanisms, this class of compounds shares the important distinction of bypassing traditional mechanisms ofAR resistance through this“event-driven” approach, such as ampliﬁcations in AR synthesis and mutations in AR binding ligand afﬁnity3. A number of AR-targeting induced proximity-based drugs are currently in development for use in mCRPC, with several mechanisms through which AR expression can be | taken advantage of or suppressed for CRPC treatment (Fig. 1). Here, we discuss two subcategories from this drug class, namely PROteolysisTArgeting Chimeras (PROTACs) and Regulated Induced Proximity TArgeting Chimeras (RIPTACs), and recent advancements in these subgroups for the treatment ofCRPC via AR-speciﬁc targeting.\u003Cbr>PROTACs PROTACswere theﬁrst ofthe rationally designed induced proximity-based drugs to be developed, with a proof-of-concept published by the Crews lab4 in 2001 ﬁrst demonstrating the potential of this class of compounds. These heterobifunctional molecules are typically comprised of three distinct subunits, with an E3 ligase targeting domain, a linker, and a protein of interest (POI) warhead that together facilitate the degradation of the POI via the ubiquitination-proteasome system. The binding of the E3 ligase binding domain and the POI binding domain to their respective targets leads to the polyubiquitination of the POI, resulting in the degradation of the target protein by proteasomes4","cbCaiqcP74Anfz0f","https://ap.wps.com/l/cbCaiqcP74Anfz0f","pdf",666281,"English","# Induced proximity-based therapeutics targeting AR in mCRPC\n## Background: ADT resistance and AR dependence\n## Event-driven pharmacology approach\n## PROTACs\n## RIPTACs","[{\"question\":\"Why do metastatic castration-resistant prostate cancers remain dependent on androgen receptor signaling?\",\"answer\":\"mCRPC continues to rely on AR signaling despite androgen-deprivation and AR-targeted therapies, often through mechanisms that compensate for AR suppression.\"},{\"question\":\"How do induced proximity-based therapeutics differ from occupancy-based inhibitors?\",\"answer\":\"Induced proximity-based drugs act via event-driven pharmacology, where transient catalytic activity enables target-effector interaction, rather than directly inhibiting the target through occupancy.\"},{\"question\":\"What are PROTACs and what is their main mechanism?\",\"answer\":\"PROTACs are heterobifunctional molecules that bring an E3 ligase and a protein of interest into proximity, promoting polyubiquitination and degradation through the ubiquitin-proteasome system.\"}]","Induced proximity-based therapeutics for advanced prostate cancer | PDF",1790112351,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bde1f4e26d8aa9dae9549e023c00a7ba.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38301e861024f7169f317987163d483c.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/544ad254dabd95af1728ce1c31a989e6.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31af1119527f9fa90cce3f9094a86dc8.webp",980,1301]